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Background. The longstanding association between the major histocompatibility complex (MHC) 
locus and schizophre-nia (SZ) risk has recently been accounted for, partially, by structural variation at 
the complement component 4 (C4) gene. This structural variation generates varying levels of C4 RNA 
expression, and genetic information from the MHC region can now be used to predict C4 RNA 
expression in the brain. Increased predicted C4A RNA expression is associated with the risk of SZ, 
aŶd Cϰ is ƌepoƌted to iŶﬂueŶĐe sǇŶaptiĐ pƌuŶiŶg iŶ aŶiŵal ŵodels. 
Methods. Based on our previous studies associating MHC SZ risk variants with poorer memory 
performance, we tested whether increased predicted C4A RNA expression was associated with 
reduced memory function in a large (n = 1238) dataset of psychosis cases and healthy participants, 
and with altered task-dependent cortical activation in a subset of these samples. 
Results. We observed that increased predicted C4A RNA expression predicted poorer performance 
on measures of memory recall (p = 0.016, corrected). Furthermore, in healthy participants, we found 
that increased predicted C4A RNA expression was associated with a pattern of reduced cortical 
activity in middle temporal cortex during a measure of visual processing (p < 0.05, corrected). 
Conclusions. These data suggest that the effects of C4 on cognition were observable at both a 
cortical and behavioural level, and may represent one mechanism by which illness risk is mediated. 
As suĐh, deﬁĐits iŶ leaƌŶiŶg aŶd ŵeŵoƌǇ ŵaǇ ƌepƌeseŶt a theƌapeutiĐ taƌget foƌ Ŷeǁ ŵoleĐulaƌ 
deǀelopŵeŶts aiŵed at alteƌiŶg Cϰ͛s deǀelopŵeŶtal ƌole. 
 
Introduction 
Schizophrenia (SZ) is a highly heritable disorder asso-ciated with disturbances in perception, 
ĐogŶitioŶ aŶd affeĐt, the ďiologiĐal ďasis of ǁhiĐh is oŶlǇ paƌtlǇ uŶdeƌstood. “uĐĐessful ideŶtiﬁĐatioŶ 
of over 100 gen-etic risk loci to date has provided an important basis from which to begin to identify 
ƌeleǀaŶt ďiologiĐal ŵeĐhaŶisŵs aŶd theiƌ fuŶĐtioŶal sigŶiﬁĐaŶĐe. ‘eĐeŶtlǇ, a studǇ of the ŵajoƌ 
histoĐoŵpatiďilitǇ Đoŵpleǆ ;MHCͿ ƌegioŶ ďǇ “ekaƌ et al. ;ϮϬϭϲͿ ideŶtiﬁed oŶe poteŶtial suĐh 
mechanism involving a locus containing the complement component 4 (C4) gene isotypes C4A and 
CϰB. IŶ that studǇ, Cϰ stƌuĐtuƌal ǀaƌiatioŶ ǁas assoĐiated ǁith sigŶiﬁĐaŶtlǇ alteƌed Cϰ ‘NA eǆpƌes-
sion (as measured in post-mortem brain tissue) such that copy number and structure of these genes 
could be used to predict C4A and C4B brain expression levels. Predicted C4A RNA expression was 
highlǇ sigŶiﬁĐaŶtlǇ assoĐiated ǁith “) ƌisk ;p = ϯ.ϲ × ϭϬ−ϮϰͿ iŶ the PsǇĐhiatƌiĐ GeŶoŵiĐs CoŶsoƌtiuŵ 
(PGC) SZ GWAS data (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), 
dƌiǀeŶ ďǇ aŶ alleliĐ seƌies of “) ƌisk leǀels that ĐoƌƌespoŶded to eaĐh allele͛s ƌelatioŶship to CϰA 
expression levels. The GWAS signal at the MHC region appeared to arise from at least three distinct 
genome-wide sigŶiﬁ-ĐaŶt sigŶals, oŶe of ǁhiĐh iŶǀolǀes this ĐolleĐtioŶ of alleliĐ iŶﬂueŶĐes oŶ CϰA 
expression. Finally, in a region of the mouse thalamus responsible for visual processing (an 
established model for experience-dependent synaptic reﬁnement) C4 RNA was expressed in neurons 
duƌiŶg a peƌiod of peak sǇŶaptiĐ pƌuŶiŶg, aŶd ŵediated sǇŶaptiĐ ƌeﬁŶeŵeŶt iŶ this sǇs-tem (Sekar et 
al. 2016). Whether or how predicted C4 expression is associated with perceptual and cognitive 
function in humans is unknown. 
The MHC region contains scores of genes with roles in the adaptive and innate immune systems and 
is the loĐatioŶ of “)͛s ŵost sigŶiﬁĐaŶt geŶetiĐ assoĐiatioŶ ;foƌ ĐoŵŵoŶ geŶetiĐ ǀaƌiatioŶͿ at a 
population level. Our group has previously reported a series of studies highlighting the cognitive and 
cortical effects of SZ-associated genetic risk loci in the MHC region and in non-MHC genes potentially 
related to comple-ment regulation. We have shown that the SZ risk allele at rs10503253 within 
CSMD1, which encodes a regula-tor of C4, was associated with poorer general cognitive ability and 
episodic memory function in large inde-pendent samples of patients and healthy participants 
(Donohoe et al. 2013). We further showed that the same risk allele was associated with reduced 
cortical activation within the occipital cortex and cuneus dur-ing a spatial working memory task 
(Rose et al. 2013). We have also shown that the SZ risk allele at rs6904071, a perfect proxy for the 
top MHC “) ƌisk “NP ƌsϭϯϭϵϰϬϱϯ ideŶtiﬁed by both the International Schizophrenia Consortium 
(Purcell et al. 2009) and Molecular Genetics of Schizophrenia (Shi et al. 2009) studies, was associated 
with episodic memory per-formance in the same large datasets, and – in a third independent sample 
– with decreased hippocampal volume (Walters et al. 2013). Given the demonstrated role for C4 in a 
model of experience-dependent synap-tiĐ pƌuŶiŶg, ǁe speĐulated that Cϰ͛s effeĐts oŶ sǇŶaptiĐ 
pruning may also be apparent behaviourally and corti-cally during performance of perceptual and 
ĐogŶitiǀe tasks. The ﬁŶdiŶgs fƌoŵ ouƌ pƌeǀious C“MDϭ aŶd MHC studies, ǁhiĐh haǀe ďeeŶ suppoƌted 
by studies of other complement genetic variants (Athanasiu et al. 2017; Zhang et al. 2017), caused us 
to speĐiﬁĐallǇ hǇpothesize a role for C4 variation in memory function. 
The purpose of the present study was to examine the relationship between predicted C4A RNA 
expression (based on structural variation in the C4 gene) and cog-nition in a large Irish sample of 
cases and healthy par-tiĐipaŶts. IŶ teƌŵs of the eǀideŶĐe aŶd justiﬁĐatioŶ foƌ the use of pƌediĐted 
C4A expression based on C4 struc-tural variation, the following is noteworthy. In the Sekar et al. 
(2016), based on eight panels of post-mortem human adult brain samples (674 samples from 245 
distinct donors in three cohorts), RNA expression of C4A and C4B increased proportionally with copy 
number of C4A and C4B, respectively; the results of these expression analyses were consistent 
aĐƌoss all ﬁǀe ďƌaiŶ ƌegioŶs aŶalǇsed. “iŵilaƌlǇ, in serum, a previous study also reported that C4 gene 
dosage was positively correlated with serum C4 pro-tein concentrations in vivo, mirroring the 
observations in the Sekar et al. post-mortem samples paper (Yang et al. 2003). Sekar et al. (2016) 
further measured C4A RNA expression levels in brain tissue samples from 35 SZ patients and 70 
individuals without SZ. The median expression of C4A in brain tissues from SZ patients was 1.4-fold 
gƌeateƌ aŶd ǁas eleǀated iŶ eaĐh of the ﬁǀe ďƌaiŶ ƌegioŶs assaǇed. This was consist-ent with earlier 
reports that elevated the levels of com-plement proteins that were present in the serum of SZ 
patients (Rudduck et al. 1985; Hakobyan et al. 2005). 
Based on this evidence above, and our previous studies, we hypothesised that increased predicted 
C4A RNA expression (which is associated with increased SZ risk) would be associated with poorer 
ŵeŵoƌǇ fuŶĐtioŶ iŶ patieŶts ǁith “) aŶd iŶ healthǇ paƌtiĐipaŶts. GiǀeŶ “ekaƌ et al.͛s ƌepoƌt that Cϰ 
expres-sioŶ ŵaǇ iŶﬂueŶĐe ǀisual deǀelopŵent in an animal model, we also investigated, using 
functional MRI, whether predicted C4A expression would explain vari-ation in cortical activity during 
a visual processing task in a healthy participant sample. 
Methods 
Participants 
In total, 908 cases and 330 healthy participants com-pleted a full neuropsychological assessment 
battery and had full genome-wide SNP data available on the basis of which predicted C4 expression 
levels could be calculated (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 
2014). Cases con-sisted of n = 676 clinically stable patients with a diagnosis of SZ and schizoaffective 
disoƌdeƌ ;“)AͿ, aŶd aŶ additioŶal Ŷ = ϮϯϮ patieŶts ǁith ͚ďƌoad seŶse͛ psǇĐhosis – diagnosed with 
either bipolar disorder with psychotic features, major depressive disorder with psychotic features, 
delusional disorder, or psych-osis Ŷot otheƌǁise speĐiﬁed. PatieŶts ǁeƌe diagŶosed ďǇ tƌaiŶed 
psychiatrists using the Structured Clinical Interview for DSM-IV Axis I Diagnosis (First, 2005). These 
patieŶts ǁeƌe ƌeĐƌuited fƌoŵ ﬁǀe sites aĐƌoss IƌelaŶd. IŶĐlusioŶ Đƌiteƌia ƌeƋuiƌed paƌtiĐipaŶts to ďe 
clinically stable at the time of cognitive assessment, aged between 18–65 years, no history of co-
morbid psychiatric disorder, no substance abuse in the preced-ing 6 months, no prior head injury 
with loss of con-sciousness, no history of seizures and with Irish ancestry (all four grandparents born 
in Ireland). 
Symptom severity was measured using the SAPS and SANS scores as previously described by us 
(Donohoe et al. 2009; Walters et al. 2010). 
Healthy participants were recruited from the general population through local media 
advertisements. All were aged between 18 and 65 years and had Irish-born paternal and maternal 
gƌaŶdpaƌeŶts, aŶd satisﬁed, oŶ the ďasis of clinical interview, the criteria of having no history of 
major mental health problems, intellectual disability or acquired brain injury, and no substance 
aďuse iŶ the pƌeĐediŶg ϲ ŵoŶths. EǆĐlusioŶ Đƌiteƌia also iŶĐluded haǀiŶg a ﬁƌst-degree relative with a 
history of psychosis. All assessments were con-ducted in accordance with the relevant ethics 
commit-tees͛ appƌoǀal fƌoŵ eaĐh paƌtiĐipatiŶg site, aŶd all paƌtiĐipaŶts pƌoǀided ǁƌitteŶ iŶfoƌŵed 
consent. In this study, healthy participants did not represent a con-trol group as no direct 
phenotypic comparison are made with patients; instead healthy participants are included both to 
establish whether comparable effects of predicted C4 expression levels were observed in both 
groups and, in a subset of these samples, to test for cortical effects using MRI. 
Cognitive assessment 
Memory recall was assessed using the Logical Memory subtest (immediate and delayed conditions) 
from the Wechsler Memory Scale, Third Edition (WMS III)(Wechsler, 1997) and the Paired Associated 
Learning task (PAL; stages completed and total errors) from the Cambridge Automated 
Neuropsychological Test Battery (Robbins et al. 1994). Working memory was assessed using the 
Spatial Working Memory (SWM) subtest from the Cambridge Automated Neuropsychological Test 
Battery (Robbins et al. 1994) and Letter-Number Sequencing (LNS task) from the WMS III. Finally, 
mea-sures of general cognitive ability (derived from the Wechsler Adult Intelligence Scale, Third 
Edition)(Wechsler, 1997) and attentional control [Continuous Performance Task, Identical Pairs 
version; CPT-IP (Cornblatt et al. 1988)] were also included as patients with SZ frequently show 
deﬁĐits iŶ these aƌeas of fuŶĐ-tion. The published norms from the Wechsler test bat-tery, the 
CANTAB test batteries, and the CPT-IP indicate a high level of test–retest validity, and, having been 
ǁidelǇ used iŶ “) ƌeseaƌĐh, haǀe ĐoŶsisteŶtlǇ shoǁed a high seŶsitiǀitǇ to ĐogŶitiǀe deﬁĐits. 
Functional MRI assessment 
A subgroup of the healthy participants (n = 87) under-went functional imaging during a visual 
processing task as described by us previously (Grosbras & Paus, 2006; Donohoe et al. 2007; Rose et 
al. 2012; Mothersill et al. 2014a, b). In this task, a face processing task developed by Grosbras & Paus 
(2006), participants watched a series of 2–5-s black-and-white videos of either contrasting circular 
images (expanding/contract-ing black-and-ǁhite ĐoŶĐeŶtƌiĐ ĐiƌĐles; ͚ďaseliŶe͛ ĐoŶdi-tion), or faces 
which started from a neutral expression, and then turned into an angry expression or neutral 
expression. Overall, there were 28 blocks of 18-s dur-ation each consisting of 4–7 video clips: nine 
ďloĐks of ĐoŶĐeŶtƌiĐ ĐiƌĐles, ﬁǀe ďloĐks of Ŷeutƌal faĐe ǀideos, ﬁǀe ďloĐks of aŶgƌǇ faĐe ǀideos. 
AtteŶtioŶ to task ǁas ĐoŶﬁƌŵed on the basis of a face recognition task following completion of the 
fMRI task and outside the scanner. Six of the 87 participants scored <4/5 on this task and were 
excluded from further analysis. 
Imputation of C4 structural variation and genetically predicted C4A expression 
Genotyping was conducted on DNA extracted from blood or saliva from patient and healthy 
participant participants. SNP data were obtained from two different sites; a GWAS using the 
Affymetrix SNP Array 6.0 platform, conducted as part of the Wellcome Trust Case Control 
Consortium 2 (Irish Schizophrenia Consortium & The Wellcome trust Case Control Consortium 2, 
2012) and a collaborative GWAS with Cardiff University using an Illumina HumanCoreExome 
(+custom) SNP array. Direct genotypes for SNPs in the region of 23–35 Mb on chromosome 6 from 
the Affymetrix (n = 3657 SNPs) and Illumina (n = 3712) data were used to impute C4 structural alleles 
and pre-dicted expression. This analysis of our data was under-taken by a member of the McCarroll 
group using the same methods described previously by them (Sekar et al. 2016). In brief, this 
involved imputation of C4 structural alleles in the study populations using a 222 haplotype 
integrated SNP and C4 reference panel. Imputed structural alleles were used to determine copy 
number of C4 structural elements (C4A, C4B, C4L and C4S and their co-occurrence) in each individ-
ual, and expected expression of C4A and C4B in the brain was inferred based on the previously 
determined relationship of copy number of C4 structural elements to gene expression in human 
brain samples. This resulted in a normally distributed range of predicted C4 expression scores of 
between 0 and 1.87 (mean 1.23, S.D. 0.45). 
Statistical analysis – neuropsychological tests 
To estimate the correlation between predicted C4A expression levels and performance of memory 
aŶd otheƌ ĐogŶitiǀe tasks, a seƌies of ĐoƌƌelatioŶal aŶalǇsis ǁas peƌfoƌŵed usiŶg PeaƌsoŶ͛s ƌ, 
folloǁed ďǇ ŵultiple ƌegƌessioŶ aŶalǇsis foƌ sigŶiﬁĐaŶt ǀaƌiaďles usiŶg IBM “P““ “tatistiĐs (IBM Corp, 
2012). As this regression analysis focused on memory tasks known to be corre-lated with each other, 
and observed here to be corre-lated with predicted C4 expression levels, an unrotated principal 
components analysis was under-taken based on the four episodic memory test available to reduce 
the multiple testing burden. This resulted in one component which explained 72% of the variance in 
memory scores being extracted (with factor loadings of 0.881 for logical memory 1, 0.889 for logical 
memory 2, 0.ϳϲϲ foƌ PAL stages aŶd −Ϭ.ϴϭϯ foƌ PAL total eƌƌoƌsͿ; paƌtiĐipaŶts sĐoƌes oŶ this faĐtoƌ 
were used as the dependent variable in the regression analysis. Age and gender were entered into 
the regression analysis as covariates of no interest. As cognitive proﬁles of patients with SZ and SZA 
are typically reported to dif-fer from other kinds of psychosis (e.g. bipolar dis-order), the analysis 
was undertaken both in the full group, and with psychosis patients with disorders other than SZ and 
SZA removed. Power calculations for these regression analyses indicated that sample sizes of n = 385 
or greater would be required to observe small effects. This suggests that in the present study of 908 
cases and 330 health participants (total sample N = 1238), we were adequately powered to detect 
small effects based on the full sample and the patient-only sample, but were somewhat 
underpowered to detect small effects in the healthy participant-only sample. 
Imaging pre-processing and statistical analysis 
Spatial pre-processing and statistical analysis of MRI data was performed using Statistical Parametric 
MappiŶg ;“PMϴ, ƌeǀisioŶ ϰϮϵϬ, http://ǁǁǁ.ﬁl.ioŶ.uĐl. aĐ.uk/spŵ/softǁaƌe/spŵϴ/Ϳ aŶd MATLAB 
R2011b (v7.13; http://www.mathworks.co.uk/). Functional images were realigned to the mean 
functional image, normalised to Montreal Neurological Institute (MNI) space with a voxel size of 3 
mm × 3 mm × 3 mm and smoothed using a 10 mm full width at half maximum (FWHM) isotropic 
GaussiaŶ ﬁlteƌ. Afteƌ spatial pƌe-processing, graphical plots of the estimated time series of 
translations and rotations were inspected for exces-siǀe ŵotioŶ, ǁhiĐh ǁe deﬁŶed as ŵoƌe thaŶ ϯ 
mm translation and/or 3° rotation. One participant was excluded from further analysis due to 
movement, and six participants were excluded due to low-ƋualitǇ M‘I data aŶd/oƌ sigŶiﬁĐaŶt 
aƌtefaĐts, ƌesultiŶg iŶ a ﬁŶal saŵple of ϳϰ paƌtiĐipaŶts. Foƌ the faĐe pƌoĐessiŶg task, thƌee task 
conditions (angry faces, neutral faces and baseline) and four contrasts consistent with our 
examination of neural activity associated with this task in SZ patients (Grosbras & Paus, 2006; 
Mothersill et al. 2014a): neutral faces v. baseline, angry faces v. baseline, all faces (angry and 
neutral) v. baseline and aŶgƌǇ faĐes ǀ. Ŷeutƌal faĐes. PaƌtiĐipaŶts͛ ĐoŶtƌast maps were entered into a 
second-level analysis to investigate effects of predicted C4 expression on neural activity. Results 
were examined at a p < 0.001 (uncor-rected) level and clusters were considered statistically 
sigŶiﬁĐaŶt at a p < Ϭ.Ϭϱ leǀel after family-wise error cor-rected for multiple comparisons across the 
ǁhole ďƌaiŶ at the Đlusteƌ leǀel. Foƌ eaĐh of these Đlusteƌs, MNI ĐooƌdiŶates of sigŶiﬁĐaŶt ŵaǆiŵa 
were entered into the Anatomy toolbox in SPM 8 (Eickhoff et al. 2005, 2006, 2007) and probable 
aŶatoŵiĐal ƌegioŶs ǁeƌe ideŶtiﬁed usiŶg the AllAƌeas_ǀϭϴ_MPM atlas. 
Results 
C4 neuropsychological results 
Demographic and clinical characteristics for patients and healthy participants appear in Table 1. 
Predicted C4A expression levels were not associated with age, gender or years of education. In terms 
of clinical symp-tom severity, no association was observed between predicted C4A RNA expression 
levels and either posi-tive, negative or disorganized symptom factor scores [based on a principal 
components analysis of SAPS and SANS scores previously described by us (Donohoe et al. 2009)]. 
Similarly, no association between predicted C4A expression and medication dosage, measured in 
terms of chlorpromazine equiva-lents was observed. 
Based on a correlational analysis, increased pre-dicted C4A RNA expression levels were associated 
with poorer performance on all indexes of both verbal and non-verbal episodic memory 
performance (see Table 2). Given the correlation between these mea-sures, to estimate the amount 
of variance in memory function explained by predicted C4A expression levels, these four memory 
sĐoƌes ǁeƌe ĐoŵďiŶed usiŶg aŶ uŶƌotated pƌiŶĐipal ĐoŵpoŶeŶts aŶalǇsis, the ﬁƌst eǆtƌaĐted 
component of which explained 72% of vari-ance on these measures. ParticipaŶt͛s sĐoƌes oŶ this 
memory factor were then used as the dependent variable in the regression analysis. After the effects 
of age and gender were accounted for (as covariates of no interest), predicted C4A expression 
ĐoŶtiŶued to sigŶiﬁĐaŶtlǇ pƌediĐt ǀaƌiation in memory performance (F change = 8.07; df = 1653; p = 
0.005), explaining 1.2%of variation in memory factor scores (see Table 3). On the basis of a 
Bonferroni correction for the four cogni-tiǀe ĐoŶstƌuĐts iŶĐluded iŶ this studǇ, this ﬁŶdiŶg suƌ-vives 
correction for multiple testing [corrected p value (0.005 × 4) = 0.02]. Re-running the analysis to 
account for diagnosis (entered as a covariate on the step prior to entering predicted C4 expression 
level), the results were unchanged (F change = 9.3; df1639; p = 0.002; r2 change = 1.1%). Similarly, 
ƌesults ƌeŵaiŶed sigŶiﬁĐaŶt ǁheŶ oŶlǇ patieŶts aŶd Ŷot healthǇ paƌtiĐipaŶts ǁeƌe iŶĐluded iŶ the 
analysis (F change = 4.71; df1499; p = 0.030; r2 change = 0.8%), or when only narrow psych-osis and 
healthy participants were included and not non-SZ psychotic cases (F change = 8.2; d = 1513; p = 
0.004; r2 change = 1.3%). Finally, in an analysis of the healthy participant group only (which was less 
than half the size of the patient sample), predicted C4 expression showed the same direction of 
assoĐiatioŶ as iŶ patieŶts ďut ǁas Ŷot statistiĐallǇ sigŶiﬁĐaŶt. 
This relationship between predicted C4A expression and episodic memory was observed in the 
absence of any correlation with working memory. Similarly, pre-dicted C4A expression was not 
observed to correlate with either general cognitive ability or attentional con-trol (see Table 2). 
 
Two other variants within the MHC region were each associated with the risk in the Sekar et al. 
studǇ, iŶdepeŶdeŶtlǇ of Cϰ aŶd of eaĐh otheƌ. Foƌ oŶe of these, ƌsϮϭϬϭϯϯ, ǁe did Ŷot ﬁŶd aŶǇ 
association with memory (r2 change = .001, N.S.). The other SNP, rs13194504, was not available in 
our dataset. Instead we use a linkage disequilibrium (LD) proxy SNP rs148082388 (r2 = 0.87) 82.5 kb 
away to investigate whether the same memory effects were associated with this SNP; a comparable 
association with poorer memory function was observed (r2 change 0.6%; F change = 4.46; p = 0.035). 
This SNP is also in moderately high LD (r2 = 0.67) with the MHC risk variant rs115329265 reported on 
by the PGC (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), for which 
we observed a similar association with poorer memory function (r2 change 0.5%; F change = 5.23; p 
= Ϭ.ϬϮϮͿ. FiŶallǇ, to ƌelate ouƌ Cϰ pƌediĐted eǆpƌessioŶ ﬁŶdiŶgs to ouƌ eaƌlieƌ ĐogŶi-tiǀe ﬁŶdiŶgs ǁith 
MHC SNP rs6904071 (Walters et al. 2013), a PeaƌsoŶ͛s ƌ ĐoƌƌelatioŶ ǁas Đaƌƌied out, ďased oŶ ǁhiĐh 
a statistiĐallǇ sigŶiﬁĐaŶt positiǀe correlation was observed (r = 0.32, df = 610, p = 7.56 × 10–16). 
C4 fMRI analysis in healthy participants 
In the subset of participants for whom fMRI data were available, differences in predicted C4A 
expression were not observed to associate with either age or gender (p > 0.05; see Table 4). A 
ŶoŵiŶallǇ sigŶiﬁĐaŶt ;positiǀeͿ ĐoƌƌelatioŶ ǁith Ǉeaƌs of eduĐatioŶ ǁas oďseƌǀed ;p = Ϭ.ϬϰͿ. We 
therefore examined the effects of education on neural activity across our sample for all 
eǆpeƌiŵeŶtal ĐoŶditioŶs eǆaŵiŶed ďut Ŷo sigŶiﬁ-cant effects of education were observed, so 
education was not considered further. 
Neural activity during face processing task 
Based on a whole brain analysis, increasing levels of genetically predicted C4A expression 
sigŶiﬁĐaŶtlǇ Đoƌ-related with decreased activity in a cluster incorporat-ing the middle temporal gyrus 
during neutral face processing compared to baseline [t(74) = 5.49; corrected p < 0.05; see Table 5 
and Fig. 1]. This relationship was also observed during angry face processing v. baseline and all faces 
v. baseline, but only at trend levels (uncor-rected p < 0.001). To check for outlier effects, each par-
tiĐipaŶt͛s ŵeaŶ paƌaŵeteƌ estiŵates for all voxels were calculated for the temporal cluster showing 
a sigŶiﬁ-cant correlation with predicted C4A expression. These parameter estimates were then 
iŶputted iŶto “P““ to ĐheĐk foƌ outlieƌ ǀalues, ǁhiĐh ǁeƌe deﬁŶed as aŶǇ ǀalue ŵoƌe thaŶ ϭ.ϱ tiŵes 
the interquartile range of the values. No outliers were detected. 
Discussion 
This study examined the effects of genetically pre-dicted C4A RNA expression on neuropsychological 
function in a large dataset of psychosis cases and healthy participants, and on task-dependent 
cortical activation during a visual task in a subset of healthy samples. Based on recent evidence of an 
association between predicted C4A RNA expression and increased SZ risk in humans, and between 
Cϰ deﬁĐieŶĐǇ aŶd alteƌed sǇŶaptiĐ pƌuŶiŶg iŶ mice (Sekar et al. 2016), and our previous 
neurocognitive studies of variants at this locus, we hypothesised that variation inpredicted C4A RNA 
expression would be associated with reduced memory function and altered neural activity. In testing 
this hypothesis, ǁe oďseƌǀed that iŶĐƌeased pƌediĐted CϰA ‘NA eǆpƌessioŶ ǁas sigŶiﬁ-cantly 
correlated with, and predictive of, poorer per-formance on measures of episodic memory in both 
patients and healthy participants. Furthermore, based on an analysis carried out in a subset of our 
healthy participants, we found that increased predicted C4A RNA expression was associated with a 
pattern of reduced cortical activity in the middle temporal gyrus during a measure of visual 
processing. 
 
 
  
 
 
AŵoŶg the ĐogŶitiǀe deﬁĐits assoĐiated ǁith “), deﬁĐits iŶ ŵeŵoƌǇ fuŶĐtioŶ aƌe aŵoŶg the laƌgest 
observed (Heinrichs & Zakzanis, 1998). The association between predicted C4A RNA expression and 
poorer episodic memory observed in this study are highly consistent with our previous studies of 
other genetic risk variants either at this locus or known to directly interact with C4. C4 was selected 
for a study by Sekar et al. (2016) on the basis of the MHC signal previously reported both in the PGC 
GWAS and by previous GWAS (Ripke et al. 2013). On the basis of our analysis of the MHC risk allele 
at rs6904071, we previously reported an association with poorer epi-sodic memory and, in an 
independent cohort, with decreased hippocampal volume. Even though the cor-relation between 
rs6904071 and predicted C4 expres-sion moderate (r2 estimate of shared variance10.2%), the 
patterns of cognitive results here are highlǇ ĐoŶsisteŶt ǁith ďoth the speĐiﬁĐ pheŶotǇpe aŶd 
direction of those previous ﬁŶdiŶgs. At pƌeseŶt, otheƌ ĐogŶitiǀe datasets iŶ ǁhiĐh pƌediĐted Cϰ 
expres-sion levels have been calculated are not available; although supportive of our earlier MHC 
ﬁŶdiŶgs, iŶdepeŶdeŶt ƌepliĐatioŶ of these ƌesults ǁill ďe ƌeƋuiƌed to ĐoŶﬁƌŵ Cϰ͛s effeĐts on 
cognition. Finally, the association with memory performance observed here is unlikely to be solely 
attributable to inattentive-ness, as these associations were observed in the absence of an 
association with attentional performance as measured by the CPT-IP. 
Sekar et al. reported two other variants within the MHC region which were each associated with risk, 
inde-pendently of C4 and of each other. Based on an analysis of an LD proxy for one of these – 
rs148082388, a com-parable association with poorer memory function was observed. As noted, this 
SNP is in moderately high LD with the MHC risk variant rs115329265 reported on by the PGC 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), and for which we 
observed a similar association with poorer memory function. While it is highly unlikely that all SZ-
associated variants within the MHC locus would show the same phenotypic effects, the consistency 
of these genetic effects on memory function is interesting. Returning to C4 in particular, the basis for 
this studǇ ƌepoƌted heƌe, it is iŶteƌestiŶg to Ŷote that “ekaƌ et al. fouŶd that of the ﬁǀe ďƌaiŶ ƌegioŶs 
assessed, cells expressing C4 were most abundant in the hippocampus, the subcortical region most 
strongly associated with memory recall. 
 
A key observation of the Sekar et al. (2016) C4 study was the observation of reduced levels of 
sǇŶaptiĐ ƌeﬁŶeŵeŶt iŶ ŵiĐe that laĐked Cϰ. IŶ aŶ eǆpeƌiŵeŶtal ŵodel of sǇŶaptiĐ pƌuŶiŶg iŶ the 
visual system, Sekar et al. reported that C4-deﬁĐieŶt ŵiĐe shoǁed deĐƌeased Cϰ eǆpƌessioŶ iŶ the 
lateral geniculate nucleus (LGN) of the visual thalamus, and that this was associated with defects in 
experience-dependent synaptic remodelling. In linking these ﬁŶdiŶgs to ouƌ ĐoƌtiĐal aĐtiǀatioŶ 
ﬁndings, in which we observed pre-dicted C4 expression-related difference in the middle temporal 
gyrus and not the thalamic regions, the fol-lowing points are noteworthy: (1) the functional spe-
cialization of C4 into C4A and C4B in humans does not have an analogy in mice, and (2) the mice 
ﬁndings related to developmental (rather than cross-sectional) differences in synaptic pruning) in 
the thalamic dLGN region; furthermore, (3) our study employed a visual processing task designed to 
index face processing – an aspect of visual information processing involving the ventral stream that 
is consistently shown to be impaired in patients with SZ (Mothersill et al. 2014a, b). Given that this 
task is uŶlikelǇ to speĐiﬁ-cally highlight regions serving basic visual processing, it is therefore 
unsurprising that the between-group dif-ferences in thalamic activation are not observed; (4) in 
genetic terms, using the same task, Dickie et al. (Dickie et al. 2014) found that task-related BOLD 
response within a cluster incorporating the middle temporal cor-tex was strongly genetically 
iŶﬂueŶĐed. CoŶsisteŶt ǁith these ﬁŶdiŶgs, ouƌ studǇ highlights the ƌole of Cϰ iŶ the aĐtiǀitǇ of the 
right middle temporal gyrus during task performance. Given that this effeĐt ǁas sigŶiﬁĐaŶt foƌ the 
neutral faces v. baseline contrast but not others (e.g. association between predicted C4 expression 
and activation during angry faces v. base-line, all faces v. baseline, did not survive correction), 
ĐoŶﬁƌŵatioŶ of these results in further samples will be important. 
The right middle temporal gyrus plays an important role in facial recognition (Carvajal et al. 2013), 
and is activated by both neutral and angry facial expressions (Fusar-Poli et al. 2009; Dickie et al. 
2014), consistent with the view that healthy participants respond simi-larly to both neutral and 
angry faces at both a behav-ioural and neural level (Lee et al. 2008; Ille et al. 2011). Nevertheless, 
participants may interpret neutral faces differently, not only due to the fact that no overt anger is 
being displayed, but also due to the presenta-tion context – for example, neutral faces are 
sometimes interpreted more positively if immediately following negative faces and more negatively 
if following happy faces (Lee et al. 2008). In this study, we found that C4A expression affected right 
middle temporal activity during both neutral and angry face processing, but this effect was only 
sigŶiﬁĐaŶt at a ĐoƌƌeĐted leǀel duƌiŶg Ŷeutƌal faĐe pƌoĐessiŶg. Futuƌe iŵagiŶg genet-ics studies based 
on face processing will be needed to examine why neural response to neutral faces might be more 
sensitive to C4A genetic variation compared to angry faces. 
Finally, in the absence of a memory component to this visual fMRI task, whether these cortical 
abnormal-ities are related to, and account for, the behavioural memory impairments observed on 
neuropsychological testing is unknown. Similarly, as there was not a behavioural component to this 
task, it was not possible to correlate task performance with memory task per-formance. Whether 
these ﬁŶdiŶgs iŵpliĐate the pleio-tropic effects of predicted C4 expression differences, or the 
behavioural and cortical effects of a common pathway, therefore, remains to be elucidated. From a 
translational perspective, this will be important for determining the extent to which any 
phaƌŵaĐologiĐal atteŵpt to taƌget the deleteƌious ĐoƌtiĐal effeĐts of Cϰ ǀaƌiatioŶ should ďe speĐiﬁĐ 
to, or broader than, mem-ory function alone. 
The ﬁŶdiŶg of Đoŵpaƌaďle ĐogŶitive effects of pre-dicted C4 expression in patients and healthy 
partici-pants is consistent with our general expectation that while risk-associated biological 
pƌoĐesses ǁill, ďǇ deﬁŶitioŶ, oĐĐuƌ at higheƌ fƌeƋueŶĐǇ iŶ Đases thaŶ ĐoŶ-trols, the phenotypic 
effects will be comparable in healthy participants who carry that risk factor. Comparable phenotypic 
effects in cases and healthy participants have previously been reported for other SZ risk variants 
(e.g. MIR137; Mothersill et al. 2014b), although for some cases this expectation has not been met 
(e.g. Walters et al. 2010). The cortical effects of pre-dicted C4 expression reported here are based on 
the analysis of healthy participants only, an approach pre-viously used in psychiatric genetics studies 
given the ĐhalleŶges of iŵagiŶg sufﬁĐieŶtlǇ laƌge saŵples of Đases. Whetheƌ the saŵe ĐoƌtiĐal effeĐts 
of C4, based on one contrast (neutral faces v. baseline) but not others (angry faces v. either neutral 
faces or baseline), will be observed in patients is currently unknown, and further imaging studies of 
patients will be required to establish how C4 expression effects visual processing in this group. 
Conclusion 
The recent association of SZ risk with increased pre-dicted C4 expression is a major step towards 
under-staŶdiŶg the aetiologǇ of “). Based oŶ the hǇpothesis that Cϰ͛s effeĐt ǁould ďe ŵost 
pronounced in cortical regions whose development is highly experience-dependent, we 
hypothesised and then observed that increased predicted C4A RNA expression was predict-ive of 
poorer memory performance and reduced cor-tical activity in middle temporal cortex during a 
measure of visual processing. Doing so further eluci-dates the pathway between genetically 
mediated altered development and illness-related disability. 
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